Update-3 11/11/26 2:45 EST…..Not much to add because we are busy with our portfolio focused on AI stocks which are hellishly volatile.The sell-off in SMID cap Biotech/genomics has abated somewhat with a major hit to ARKG down 4.5%,GH down 5% MTD, ILMN down 20% MTD.

The bull market in biotech is intact with the IBB up 8.9%% MTD and seasonality should carry us through till mid-January.

Update-2 …11/9/26-10:45am EST.. XENCOR… one of our top SMID cap biotech picks is trading at new highs;$37+ with a market cap of only $2.68B presented data at the ACR for an engineered bispecific Antibody in Phase 1b study for Rheumatoid Arthritis.

  • Nice rally today with XBI up 2.34% to $155.84.
  • Other big 4% +movers from our focus list: ADPT, AMRX, COGT, DNTH, IMVT, ROIV, etc.
  • If you want to add a balanced position in biotech check out TRowePrice (PRHSX) up 29% over one year.

 

  • Update-1…11/4/26 240P EST…DEMs Win should support further healthcare gains: XLV up 2.83% at $189 ; latest new pick GE Healthcare(GEHC) continues to show gains up 34% MTD at $86. IBB up 1.78% to $219 at a double top. MEDtech on the move with ABT up 5.8%, BDX up 5.22%,ISRG up  9.2%. XNCR up 11% to $34 on an upgrade 

Biotechnology Leadership with Strong  Growth and Earnings

  • IBB is 28.94% YTD and 4.74% week to date.; XBI is up 27.94% YTD and 4.31% WTD. But off highs for year.
  • ARKG genomics is up 6.73% WTD and 77% YTD but down on Friday as RSI weakens (Genomics too frothy?).
  • XLV healthcare is up 3.2% WTD and 19.43% YTD. Tools (TMO) and Providers (UNH) show gains as well.

If you have been reading Raygent.com you’ll see the gradual uptick in the XLV beginning with the strength in large cap biotechnology stocks in June then gradually moving up 7.8% over the past month with strength in other other sub-sectors like providers United Health (UNH) and lately tools and diagnostics Thermo Fisher (TMO). But a word of caution -we need to understand the recent weakness in genomics stocks like ILMN and GH.

Large Cap Biopharmaceuticals -Your Core Positions for a Healthcare Portfolio

Large cap biopharmaceutical stocks had a great week no surprise to those following the sector because of stable growth, fantastic earnings reports and defensive nature when compared to technology stocks. And look at the Forward PEs in most cases less than 20. Here are some of this past week’s earnings reports:

LONG: ABBV, BIIB,GILD, LLY, MRK,PFE, REGN., VRTX.

COMPANY TIcker P Mkt Cap % YTD RSI P 10/18 % WTD P 10/30 WTD
$B
Abbvie ABBV 276.47 521 29 73 285.42 3.24 294 3.24
Amgen AMGN 414.87 2224 42.4 72 432.43 4.25 466 6.09
Gilead Sciences GILD 151.17 211.6 23 74.3 162.1 3.32 170.7 9.38
Johnson and J JNJ 261.44 658 32 60.3 255.56 -2.25 273.2 3.56
Eli Lilly LLY 1179 1110 31.9 77.9 1257 6.59 1417 11.3
Merck MRK 145.6 359 42 57 145.95 0.24 149.5 2.93
Pfizer PFE 28.28 161 22.57 66.5 29.58 4.6 30.52 1.63
Vertex VRTX 510 129 23.3 67.6 499.74 -1.77 558.9 6.67
ARK GEnomic Rev ARKG 77.4 40.7 46.7 -8.97 51.4 6.73
iShares Biotech IBB 28.9 62.8 202 -2.18 217.6 4.75
State ST SPDR XBI 27.8 54 144.32 -6.15 156 4.31

Pin It on Pinterest